Getinge Interim Report January-March 2026
In the first quarter of 2026, Getinge reported an organic growth of 0.8% in net sales and 3.9% in order intake, setting a new record for this period despite a decline in Acute Care Therapies. Significant achievements included strong growth in Surgical Workflows and Life Science segments, alongside a robust adjusted EBITA margin. A CE mark for the Cardiohelp II ECLS system and EU MDR approval for the Intergard Synergy graft were also highlights. The company maintains a forecast for 3-5% organic sales growth for 2026 amidst geopolitical uncertainties.
GOTHENBURG, Sweden, April 21, 2026 /PRNewswire/ — “We succeeded in surpassing last year’s record-breaking first quarter with organic growth in both net sales and order intake,” says Mattias Perjos, President & CEO at Getinge. The medtech company’s net sales increased organically by 0.8%…